Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder

NCT01825837 is registered in ClinicalTrials.gov with Bial - Portela C S.A. as lead sponsor.

NCT NCT01825837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01825837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder
Lead sponsor
Bial - Portela C S.A.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2007
Enrollment
104 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder